This study reviewed the safety of adipose-derived cell therapy. Thromboembolic complications were noted following systemic administration of cells. The treatment has so far shown to be safe in the setting of previous cancer. Donor specific antibodies are produced when using allogeneic cells documenting that these cells are not immune privileged. The consequences of this needs further research. Future research should focus on higher quality of reporting of adverse events as the present literature is of low quality.